Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490311 | 1.00 | SLC9A1 (0.48) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL3330921 | 0.86 | HCAR3 (0.50) | SLC9A1KEAP1HCAR3HPGDKDM4E | |
| SCHEMBL12560105 | 0.84 | SLC9A1 (0.50) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL1161111 | 0.82 | KEAP1 (0.48) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL29975783 | 0.82 | SLC9A1 (0.48) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL22862868 | 0.82 | KEAP1 (0.48) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL282111 | 0.82 | SLC9A1 (0.48) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL8828592 | 0.81 | SLC9A1 (0.47) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL10130169 | 0.79 | KEAP1 (0.46) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 | |
| SCHEMBL8771320 | 0.79 | SLC9A1 (0.46) | SLC9A1KEAP1SLC6A4CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-0641785-B1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 1999-10-27 | — | — | EP | disclosed |
| US-5674886-A | AROMATASE INHIBITOR; BREAST CANCER; UROGENITAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-07 | — | — | US | disclosed |
| EP-0641785-A1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992022536-A1 | VINYLIMIDAZOLES, VINYLTRIAZOLES AND VINYLTETRAZOLES WITH A BICYCLIC SUBSTITUENT GROUP | SCHERING AKTIENGESELLSCHAFT, BERLIN UND BERGKAMEN (DE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518457-A1 | Bicyclic substituted vinylimidazoles, -triazoles and -tetrazoles | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | SLC9A1 4345/4885KEAP1 2972/4885SLC6A4 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.